ASPM Can Be Used as a Marker for the Diagnosis and Prediction of Progression-Free Intervals in Patients with Bladder Urothelial Carcinoma

نویسندگان

1 Department of Urology, Affiliated Hospital of Guangdong Medical University, Zhanjiang City 524000, Guangdong Province, China

2 Department of Urology, Affiliated Hospital of Guangdong Medical University, Zhanjiang City 524000, Guangdong Province, China

3 Department of Urology, Affiliated Hospital of Guangdong Medical University, Zhanjiang City 524000, Guangdong Province, China

4 Department of Urology, Affiliated Hospital of Guangdong Medical University, Zhanjiang City 524000, Guangdong Province, China

5 The First Clinical College, Guangdong Medical University, Zhanjiang City 524000, Guangdong Province, China

doi
10.22034/ircmj.2025.509367.1939
چکیده

   Background and Objectives: The abnormal spindle-like microcephaly-associated gene (ASPM) plays a crucial role in the formation of the mitotic spindle and neurogenesis. ASPM may also contribute to the development of various cancers. Investigate the role of ASPM in bladder urothelial carcinoma (BLCA).    Methods: The expression differences of ASPM between unmatched samples were analyzed with the Welch T-test and between paired samples with the paired sample t-test. Evaluating the effectiveness of ASPM in diagnosing BLCA with ROC analysis. Determining the prognostic factors in the ASPM high-expression group and the low-expression group with Cox regression analysis. The relationship between ASPM and immune cells was analyzed through Spearman correlation.    Results: The ROC curve showed that ASPM had a high diagnostic ability for BLCA. Patients with high expression of ASPM had a shorter progression-free interval (PFI). GO and KEGG analyses revealed that ASPM-related DEGs were associated mainly with ubiquitin-mediated proteolysis. ASPM expression in BLCA was positively correlated with the infiltration of Th2 cells and T helper cells. ASPM was negatively correlated with the infiltration of pDC, NK CD56bright cells and Mast cells. The above findings are merely correlational studies and require further in vitro or in vivo experiments for functional validation.    Conclusion: ASPM is an effective biomarker for diagnosing and predicting PFI in patients with BLCA. Therefore, ASPM is expected to become a potential target for the treatment of BLCA. Further research is still needed to confirm these conclusions, such as conducting in vitro knockout experiments, carrying out prospective cohort studies, or using immunohistochemistry (IHC) for verification.